Miklos Pless
Overview
Explore the profile of Miklos Pless including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
2779
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
de Langen A, Johnson M, Mazieres J, Dingemans A, Mountzios G, Pless M, et al.
Lancet
. 2023 Feb;
401(10378):733-746.
PMID: 36764316
Background: Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer...
12.
Papachristofilou A, Bedke J, Hayoz S, Schratzenstaller U, Pless M, Hentrich M, et al.
Lancet Oncol
. 2022 Oct;
23(11):1441-1450.
PMID: 36228644
Background: Standard treatment options for patients with stage IIA or stage IIB seminoma include either para-aortic and pelvic radiotherapy or three to four cycles of cisplatin-based combination chemotherapy. These options...
13.
Furrer K, Weder W, Eboulet E, Betticher D, Pless M, Stupp R, et al.
J Thorac Cardiovasc Surg
. 2022 Jun;
164(6):1587-1602.e5.
PMID: 35688713
Objective: Surgical treatment of locally advanced non-small cell lung cancer including single or multilevel N2 remains a matter of debate. Several trials demonstrate that selected patients benefit from surgery if...
14.
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565320
Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland. Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites...
15.
Lotscher J, Marti I Lindez A, Kirchhammer N, Cribioli E, Giordano Attianese G, Trefny M, et al.
Cell
. 2022 Jan;
185(4):585-602.e29.
PMID: 35051368
The relevance of extracellular magnesium in cellular immunity remains largely unknown. Here, we show that the co-stimulatory cell-surface molecule LFA-1 requires magnesium to adopt its active conformation on CD8 T ...
16.
Vuong D, Bogowicz M, Wee L, Riesterer O, Badra E, DCruz L, et al.
Sci Rep
. 2021 Oct;
11(1):20890.
PMID: 34686719
The anatomical location and extent of primary lung tumors have shown prognostic value for overall survival (OS). However, its manual assessment is prone to interobserver variability. This study aims to...
17.
Oliveira C, Amstutz F, Vuong D, Bogowicz M, Hullner M, Foerster R, et al.
EJNMMI Res
. 2021 Aug;
11(1):79.
PMID: 34417899
Background: Radiomics is a promising tool for identifying imaging-based biomarkers. Radiomics-based models are often trained on single-institution datasets; however, multi-centre imaging datasets are preferred for external generalizability owing to the...
18.
Rothschild S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, et al.
J Clin Oncol
. 2021 Jul;
39(26):2872-2880.
PMID: 34251873
Purpose: For patients with resectable stage IIIA(N2) non-small-cell lung cancer, neoadjuvant chemotherapy with cisplatin and docetaxel followed by surgery resulted in a 1-year event-free survival (EFS) rate of 48% in...
19.
Denzler S, Vuong D, Bogowicz M, Pavic M, Frauenfelder T, Thierstein S, et al.
Br J Radiol
. 2021 Feb;
94(1120):20200947.
PMID: 33544646
Objectives: In this study, we aimed to assess the impact of different CT reconstruction kernels on the stability of radiomic features and the transferability between different diseases and tissue types....
20.
Hafliger S, Seidel A, Schoch E, Reichmann J, Wild D, Steinmann-Schwager S, et al.
Case Rep Oncol
. 2021 Jan;
13(3):1373-1380.
PMID: 33442358
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can...